Neuropsychiatric Drugs Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion
Loading…

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Neuropsychiatric Drugs Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

  • North America — United States, Canada, Mexico
  • Europe — United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe
  • Asia Pacific — China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC
  • South America — Brazil, Argentina, Colombia, Peru, Chile, Rest of South America
  • Middle East — Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East
  • Africa — East Africa, West Africa, North Africa, South Africa

Region / Country 2021 (A)2025 (A)2033 (P) CAGR

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis


Market size by (Illustrative, 2025)
Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitive Landscape

The pharmaceutical and healthcare industry is highly competitive, with players expanding through product launches, M&A, partnerships, and regulatory approvals. The Neuropsychiatric Drugs Market Analysis market report covers financials, market share, SWOTs, and responses to Tariffs, while providing global, regional, and country-level forecasts supported by value chain, patent analysis, and a competitive matrix serving as a key resource for stakeholders and investors.

Click any bar or cell to request the full company profile
Company2022 (A)2023 (A)2024 (A)2025 (A)
Novartis••• ••• ••• •••
Pfizer••• ••• ••• •••
Otsuka••• ••• ••• •••
Allergan••• ••• ••• •••
Eli Lilly••• ••• ••• •••
Sunovion••• ••• ••• •••
Astrazeneca••• ••• ••• •••
Actavis Laboratories••• ••• ••• •••
Johnson & Johnson••• ••• ••• •••
Bristol Myers••• ••• ••• •••
Sage Therapeutics••• ••• ••• •••
Blackthorn Therapeutics••• ••• ••• •••
H Lundbeck A/S••• ••• ••• •••
Takeda••• ••• ••• •••
Cerevel Therapeutics Llc••• ••• ••• •••

Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.

Request company profile for validation →

Report Scope & Analysis

The global neuropsychiatric drugs market is poised for significant growth, driven by the increasing global prevalence of mental health disorders such as depression, anxiety, schizophrenia, and bipolar disorder. Enhanced awareness and gradual destigmatization of mental illness are encouraging more individuals to seek diagnosis and treatment, thereby expanding the patient pool. Technological advancements in neuroscience and drug discovery are paving the way for more targeted and effective therapies. However, the market faces challenges, including the high failure rate of CNS drug clinical trials, patent expirations of key blockbuster drugs leading to generic competition, and stringent regulatory approval processes. The future landscape will be shaped by the development of personalized medicine, the integration of digital therapeutics, and expansion into untapped emerging markets with significant unmet medical needs.

Key strategic insights from our comprehensive analysis reveal:

  • A paradigm shift towards precision psychiatry is underway, with companies leveraging biomarkers and genetic profiling to develop targeted therapies for specific patient subpopulations, moving away from a one-size-fits-all approach.
  • The integration of digital therapeutics (DTx) as adjuncts to pharmacological treatments is becoming a critical differentiator, offering enhanced patient monitoring, adherence, and behavioral support.
  • Strategic focus on developing drugs with novel mechanisms of action is essential to address the significant unmet needs in treatment-resistant conditions and to overcome the challenges posed by generic erosion of established drug classes.

Strategic Recommendations for Manufacturers

Manufacturers should prioritize investment in R&D for first-in-class therapies targeting novel pathways to address treatment-resistant patient populations and build a sustainable competitive advantage. Forging strategic alliances with technology companies is crucial to develop integrated care solutions that combine pharmacotherapy with digital therapeutics, enhancing treatment efficacy and patient engagement. Furthermore, focusing on geographic expansion into high-growth emerging markets in the Asia-Pacific and Latin America, coupled with patient assistance programs to improve access and affordability, will be key to capturing future market share and driving long-term growth.

The pharmaceutical and healthcare industry is growing rapidly, driven by aging populations, chronic disease prevalence, and rising healthcare spending. Innovations in precision medicine, gene therapy, and digital health are improving outcomes, though challenges include high R&D costs, strict regulations, and pricing pressures. Growth opportunities lie in emerging markets with expanding healthcare infrastructure, while key trends such as AI-driven personalized medicine, telehealth, and sustainable pharma solutions are reshaping the industry.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Neuropsychiatric Drugs Market Analysis is witnessing significant growth in the near future.

In 2023, the Typical antipsychotics segment accounted for a notable share of the Neuropsychiatric Drugs Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst · Cognitive Market Research
LinkedIn Profile Book Appointment

Frequently Asked Questions

Neuropsychiatric Drugs Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Novartis, Pfizer, Otsuka, Allergan, Eli Lilly, Sunovion, Astrazeneca, Actavis Laboratories, Johnson & Johnson, Bristol Myers, Sage Therapeutics, Blackthorn Therapeutics, H Lundbeck A/S, Takeda, Cerevel Therapeutics Llc and others are profiled in the report.
Segments include Drug Type, Indication and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Neuropsychiatric Drugs Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
License Edition

Drug Type Typical antipsychotics, Atypical antipsychotics
Indication Bipolar disorder, Schizophrenia, Psychotic depression, Others
Route of Administration Parenteral route, Oral route
List of Competitors Novartis, Pfizer, Otsuka, Allergan, Eli Lilly, Sunovion, Astrazeneca, Actavis Laboratories, Johnson & Johnson, Bristol Myers, Sage Therapeutics, Blackthorn Therapeutics, H Lundbeck A/S, Takeda, Cerevel Therapeutics Llc

  • 1.1 Global Power Realignment & Strategic Alliances
  • 1.2 Geopolitical Risk Landscape & Conflict Hotspots
  • 1.3 International Trade Relations & Market Access Environment
  • 1.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
  • 1.5 Supply Chain Resilience, Localization & Resource Nationalism
  • 1.6 Technology Sovereignty & Digital Geopolitics
  • 1.7 Strategic Implications for Investment, Growth & Market Entry

  • 2.1 Competitive Landscape Disruption & Strategic Shifts
  • 2.2 AI-Driven Transformation of Industry Value Chain
  • 2.3 Evolution of Business Models & Revenue Streams
  • 2.4 Operational Efficiency & Cost Structure Transformation
  • 2.5 Product, Service & Innovation Acceleration
  • 2.6 Customer Behavior & Demand Evolution
  • 2.7 Future Outlook: AI-Led Market Evolution & Strategic Implications

  • 3.1 Global Neuropsychiatric Drugs Revenue Market Size, Trend Analysis 2022 - 2034
  • 3.2 Global Neuropsychiatric Drugs Volume Market Sales, Trend Analysis 2022 - 2034

  • Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

    3.3 Global Neuropsychiatric Drugs Market Size By Regions 2022 - 2034
    • 3.3.1 Global Neuropsychiatric Drugs Revenue Market Size By Region
    • 3.3.2 Global Neuropsychiatric Drugs Volume Market Sales By Region
  • 3.4 Global Neuropsychiatric Drugs Market Size By Drug Type 2022 - 2034
    • 3.4.1 Typical antipsychotics Market Size
    • 3.4.2 Atypical antipsychotics Market Size
  • 3.5 Global Neuropsychiatric Drugs Volume Market Sales By Drug Type 2022 - 2034
    • 3.5.1 Typical antipsychotics Sales Volume
    • 3.5.2 Atypical antipsychotics Sales Volume
  • 3.6 Global Neuropsychiatric Drugs Market Size By Indication 2022 - 2034
    • 3.6.1 Bipolar disorder Market Size
    • 3.6.2 Schizophrenia Market Size
    • 3.6.3 Psychotic depression Market Size
    • 3.6.4 Others Market Size
  • 3.7 Global Neuropsychiatric Drugs Volume Market Sales By Indication 2022 - 2034
    • 3.7.1 Bipolar disorder Sales Volume
    • 3.7.2 Schizophrenia Sales Volume
    • 3.7.3 Psychotic depression Sales Volume
    • 3.7.4 Others Sales Volume
  • 3.8 Global Neuropsychiatric Drugs Market Size By Route of Administration 2022 - 2034
    • 3.8.1 Parenteral route Market Size
    • 3.8.2 Oral route Market Size
  • 3.9 Global Neuropsychiatric Drugs Volume Market Sales By Route of Administration 2022 - 2034
    • 3.9.1 Parenteral route Sales Volume
    • 3.9.2 Oral route Sales Volume
  • 3.10 Global Level Competitor Analysis (Subject to Data Availability (Private Players))

  • You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)

    3.11 Executive Summary Global Market (2021 vs 2025 vs 2033)
    • 3.11.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
    • 3.11.2 Regional Volume Market Summary 2021 vs 2025 vs 2033
    • 3.11.3 Global Market Revenue Split By Drug Type
    • 3.11.4 Global Volume Market Split By Drug Type
    • 3.11.5 Global Market Revenue Split By Indication
    • 3.11.6 Global Volume Market Split By Indication
    • 3.11.7 Global Market Revenue Split By Route of Administration
    • 3.11.8 Global Volume Market Split By Route of Administration

    • Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable

      3.11.9 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities

  • 4.1 North America Neuropsychiatric Drugs Market Outlook
    • 4.1.1 North America Neuropsychiatric Drugs Market Size 2022 - 2034
    • 4.1.2 North America Neuropsychiatric Drugs Volume Market Sales 2022 - 2034
    • 4.1.3 North America Neuropsychiatric Drugs Market Size By Country 2022 - 2034
    • 4.1.4 North America Neuropsychiatric Drugs Volume Market Sales By Country 2022 - 2034
    • 4.1.5 North America Neuropsychiatric Drugs Market Size by Drug Type 2022 - 2034
      • 4.1.5.1 North America Typical antipsychotics Market Size
      • 4.1.5.2 North America Atypical antipsychotics Market Size
    • 4.1.6 North America Neuropsychiatric Drugs Volume Market Sales by Drug Type 2022 - 2034
      • 4.1.6.1 North America Typical antipsychotics Sales Volume
      • 4.1.6.2 North America Atypical antipsychotics Sales Volume
    • 4.1.7 North America Neuropsychiatric Drugs Market Size by Indication 2022 - 2034
      • 4.1.7.1 North America Bipolar disorder Market Size
      • 4.1.7.2 North America Schizophrenia Market Size
      • 4.1.7.3 North America Psychotic depression Market Size
      • 4.1.7.4 North America Others Market Size
    • 4.1.8 North America Neuropsychiatric Drugs Volume Market Sales by Indication 2022 - 2034
      • 4.1.8.1 North America Bipolar disorder Sales Volume
      • 4.1.8.2 North America Schizophrenia Sales Volume
      • 4.1.8.3 North America Psychotic depression Sales Volume
      • 4.1.8.4 North America Others Sales Volume
    • 4.1.9 North America Neuropsychiatric Drugs Market Size by Route of Administration 2022 - 2034
      • 4.1.9.1 North America Parenteral route Market Size
      • 4.1.9.2 North America Oral route Market Size
    • 4.1.10 North America Neuropsychiatric Drugs Volume Market Sales by Route of Administration 2022 - 2034
      • 4.1.10.1 North America Parenteral route Sales Volume
      • 4.1.10.2 North America Oral route Sales Volume

  • 5.1 Europe Neuropsychiatric Drugs Market Outlook
    • 5.1.1 Europe Neuropsychiatric Drugs Market Size 2022 - 2034
    • 5.1.2 Europe Neuropsychiatric Drugs Volume Market Sales 2022 - 2034
    • 5.1.3 Europe Neuropsychiatric Drugs Market Size By Country 2022 - 2034
    • 5.1.4 Europe Neuropsychiatric Drugs Volume Market Sales By Country 2022 - 2034
    • 5.1.5 Europe Neuropsychiatric Drugs Market Size by Drug Type 2022 - 2034
      • 5.1.5.1 Europe Typical antipsychotics Market Size
      • 5.1.5.2 Europe Atypical antipsychotics Market Size
    • 5.1.6 Europe Neuropsychiatric Drugs Volume Market Sales by Drug Type 2022 - 2034
      • 5.1.6.1 Europe Typical antipsychotics Sales Volume
      • 5.1.6.2 Europe Atypical antipsychotics Sales Volume
    • 5.1.7 Europe Neuropsychiatric Drugs Market Size by Indication 2022 - 2034
      • 5.1.7.1 Europe Bipolar disorder Market Size
      • 5.1.7.2 Europe Schizophrenia Market Size
      • 5.1.7.3 Europe Psychotic depression Market Size
      • 5.1.7.4 Europe Others Market Size
    • 5.1.8 Europe Neuropsychiatric Drugs Volume Market Sales by Indication 2022 - 2034
      • 5.1.8.1 Europe Bipolar disorder Sales Volume
      • 5.1.8.2 Europe Schizophrenia Sales Volume
      • 5.1.8.3 Europe Psychotic depression Sales Volume
      • 5.1.8.4 Europe Others Sales Volume
    • 5.1.9 Europe Neuropsychiatric Drugs Market Size by Route of Administration 2022 - 2034
      • 5.1.9.1 Europe Parenteral route Market Size
      • 5.1.9.2 Europe Oral route Market Size
    • 5.1.10 Europe Neuropsychiatric Drugs Volume Market Sales by Route of Administration 2022 - 2034
      • 5.1.10.1 Europe Parenteral route Sales Volume
      • 5.1.10.2 Europe Oral route Sales Volume

  • 6.1 Asia Pacific Neuropsychiatric Drugs Market Outlook
    • 6.1.1 Asia Pacific Neuropsychiatric Drugs Market Size 2022 - 2034
    • 6.1.2 Asia Pacific Neuropsychiatric Drugs Volume Market Sales 2022 - 2034
    • 6.1.3 Asia Pacific Neuropsychiatric Drugs Market Size By Country 2022 - 2034
    • 6.1.4 Asia Pacific Neuropsychiatric Drugs Volume Market Sales By Country 2022 - 2034
    • 6.1.5 Asia Pacific Neuropsychiatric Drugs Market Size by Drug Type 2022 - 2034
      • 6.1.5.1 Asia Pacific Typical antipsychotics Market Size
      • 6.1.5.2 Asia Pacific Atypical antipsychotics Market Size
    • 6.1.6 Asia Pacific Neuropsychiatric Drugs Volume Market Sales by Drug Type 2022 - 2034
      • 6.1.6.1 Asia Pacific Typical antipsychotics Sales Volume
      • 6.1.6.2 Asia Pacific Atypical antipsychotics Sales Volume
    • 6.1.7 Asia Pacific Neuropsychiatric Drugs Market Size by Indication 2022 - 2034
      • 6.1.7.1 Asia Pacific Bipolar disorder Market Size
      • 6.1.7.2 Asia Pacific Schizophrenia Market Size
      • 6.1.7.3 Asia Pacific Psychotic depression Market Size
      • 6.1.7.4 Asia Pacific Others Market Size
    • 6.1.8 Asia Pacific Neuropsychiatric Drugs Volume Market Sales by Indication 2022 - 2034
      • 6.1.8.1 Asia Pacific Bipolar disorder Sales Volume
      • 6.1.8.2 Asia Pacific Schizophrenia Sales Volume
      • 6.1.8.3 Asia Pacific Psychotic depression Sales Volume
      • 6.1.8.4 Asia Pacific Others Sales Volume
    • 6.1.9 Asia Pacific Neuropsychiatric Drugs Market Size by Route of Administration 2022 - 2034
      • 6.1.9.1 Asia Pacific Parenteral route Market Size
      • 6.1.9.2 Asia Pacific Oral route Market Size
    • 6.1.10 Asia Pacific Neuropsychiatric Drugs Volume Market Sales by Route of Administration 2022 - 2034
      • 6.1.10.1 Asia Pacific Parenteral route Sales Volume
      • 6.1.10.2 Asia Pacific Oral route Sales Volume

  • 7.1 South America Neuropsychiatric Drugs Market Outlook
    • 7.1.1 South America Neuropsychiatric Drugs Market Size 2022 - 2034
    • 7.1.2 South America Neuropsychiatric Drugs Volume Market Sales 2022 - 2034
    • 7.1.3 South America Neuropsychiatric Drugs Market Size By Country 2022 - 2034
    • 7.1.4 South America Neuropsychiatric Drugs Volume Market Sales By Country 2022 - 2034
    • 7.1.5 South America Neuropsychiatric Drugs Market Size by Drug Type 2022 - 2034
      • 7.1.5.1 South America Typical antipsychotics Market Size
      • 7.1.5.2 South America Atypical antipsychotics Market Size
    • 7.1.6 South America Neuropsychiatric Drugs Volume Market Sales by Drug Type 2022 - 2034
      • 7.1.6.1 South America Typical antipsychotics Sales Volume
      • 7.1.6.2 South America Atypical antipsychotics Sales Volume
    • 7.1.7 South America Neuropsychiatric Drugs Market Size by Indication 2022 - 2034
      • 7.1.7.1 South America Bipolar disorder Market Size
      • 7.1.7.2 South America Schizophrenia Market Size
      • 7.1.7.3 South America Psychotic depression Market Size
      • 7.1.7.4 South America Others Market Size
    • 7.1.8 South America Neuropsychiatric Drugs Volume Market Sales by Indication 2022 - 2034
      • 7.1.8.1 South America Bipolar disorder Sales Volume
      • 7.1.8.2 South America Schizophrenia Sales Volume
      • 7.1.8.3 South America Psychotic depression Sales Volume
      • 7.1.8.4 South America Others Sales Volume
    • 7.1.9 South America Neuropsychiatric Drugs Market Size by Route of Administration 2022 - 2034
      • 7.1.9.1 South America Parenteral route Market Size
      • 7.1.9.2 South America Oral route Market Size
    • 7.1.10 South America Neuropsychiatric Drugs Volume Market Sales by Route of Administration 2022 - 2034
      • 7.1.10.1 South America Parenteral route Sales Volume
      • 7.1.10.2 South America Oral route Sales Volume

  • 8.1 Middle East Neuropsychiatric Drugs Market Outlook
    • 8.1.1 Middle East Neuropsychiatric Drugs Market Size 2022 - 2034
    • 8.1.2 Middle East Neuropsychiatric Drugs Volume Market Sales 2022 - 2034
    • 8.1.3 Middle East Neuropsychiatric Drugs Market Size By Country 2022 - 2034
    • 8.1.4 Middle East Neuropsychiatric Drugs Volume Market Sales By Country 2022 - 2034
    • 8.1.5 Middle East Neuropsychiatric Drugs Market Size by Drug Type 2022 - 2034
      • 8.1.5.1 Middle East Typical antipsychotics Market Size
      • 8.1.5.2 Middle East Atypical antipsychotics Market Size
    • 8.1.6 Middle East Neuropsychiatric Drugs Volume Market Sales by Drug Type 2022 - 2034
      • 8.1.6.1 Middle East Typical antipsychotics Sales Volume
      • 8.1.6.2 Middle East Atypical antipsychotics Sales Volume
    • 8.1.7 Middle East Neuropsychiatric Drugs Market Size by Indication 2022 - 2034
      • 8.1.7.1 Middle East Bipolar disorder Market Size
      • 8.1.7.2 Middle East Schizophrenia Market Size
      • 8.1.7.3 Middle East Psychotic depression Market Size
      • 8.1.7.4 Middle East Others Market Size
    • 8.1.8 Middle East Neuropsychiatric Drugs Volume Market Sales by Indication 2022 - 2034
      • 8.1.8.1 Middle East Bipolar disorder Sales Volume
      • 8.1.8.2 Middle East Schizophrenia Sales Volume
      • 8.1.8.3 Middle East Psychotic depression Sales Volume
      • 8.1.8.4 Middle East Others Sales Volume
    • 8.1.9 Middle East Neuropsychiatric Drugs Market Size by Route of Administration 2022 - 2034
      • 8.1.9.1 Middle East Parenteral route Market Size
      • 8.1.9.2 Middle East Oral route Market Size
    • 8.1.10 Middle East Neuropsychiatric Drugs Volume Market Sales by Route of Administration 2022 - 2034
      • 8.1.10.1 Middle East Parenteral route Sales Volume
      • 8.1.10.2 Middle East Oral route Sales Volume

  • 9.1 Africa Neuropsychiatric Drugs Market Outlook
    • 9.1.1 Africa Neuropsychiatric Drugs Market Size 2022 - 2034
    • 9.1.2 Africa Neuropsychiatric Drugs Volume Market Sales 2022 - 2034
    • 9.1.3 Africa Neuropsychiatric Drugs Market Size By Country 2022 - 2034
    • 9.1.4 Africa Neuropsychiatric Drugs Volume Market Sales By Country 2022 - 2034
    • 9.1.5 Africa Neuropsychiatric Drugs Market Size by Drug Type 2022 - 2034
      • 9.1.5.1 Africa Typical antipsychotics Market Size
      • 9.1.5.2 Africa Atypical antipsychotics Market Size
    • 9.1.6 Africa Neuropsychiatric Drugs Volume Market Sales by Drug Type 2022 - 2034
      • 9.1.6.1 Africa Typical antipsychotics Sales Volume
      • 9.1.6.2 Africa Atypical antipsychotics Sales Volume
    • 9.1.7 Africa Neuropsychiatric Drugs Market Size by Indication 2022 - 2034
      • 9.1.7.1 Africa Bipolar disorder Market Size
      • 9.1.7.2 Africa Schizophrenia Market Size
      • 9.1.7.3 Africa Psychotic depression Market Size
      • 9.1.7.4 Africa Others Market Size
    • 9.1.8 Africa Neuropsychiatric Drugs Volume Market Sales by Indication 2022 - 2034
      • 9.1.8.1 Africa Bipolar disorder Sales Volume
      • 9.1.8.2 Africa Schizophrenia Sales Volume
      • 9.1.8.3 Africa Psychotic depression Sales Volume
      • 9.1.8.4 Africa Others Sales Volume
    • 9.1.9 Africa Neuropsychiatric Drugs Market Size by Route of Administration 2022 - 2034
      • 9.1.9.1 Africa Parenteral route Market Size
      • 9.1.9.2 Africa Oral route Market Size
    • 9.1.10 Africa Neuropsychiatric Drugs Volume Market Sales by Route of Administration 2022 - 2034
      • 9.1.10.1 Africa Parenteral route Sales Volume
      • 9.1.10.2 Africa Oral route Sales Volume

  • 10.1 Top Competitors Analysis

    • (Subject to Data Availability (Private Players))

      10.1.1 Global Neuropsychiatric Drugs Market Revenue and Share by Key Players
    • 10.1.2 Global Neuropsychiatric Drugs Market Volume and Share by Key Players
    • 10.1.3 Top Players Ranking 2024
    • 10.1.4 New Product Launch Analysis
    • 10.1.5 Industry Mergers and Acquisition Analysis
  • 10.2 Company Profile (Data Subject to Availability) Sample Format

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.1 Novartis
      • 10.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.1.2 Business Overview
      • 10.2.1.3 Financials (Subject to data availability)
      • 10.2.1.4 R&D Investment (Subject to data availability)
      • 10.2.1.5 Product Types Specification
      • 10.2.1.6 Business Strategy
      • 10.2.1.7 Recent Developments
      • 10.2.1.8 Management Change
      • 10.2.1.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.2 Pfizer
      • 10.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.2.2 Business Overview
      • 10.2.2.3 Financials (Subject to data availability)
      • 10.2.2.4 R&D Investment (Subject to data availability)
      • 10.2.2.5 Product Types Specification
      • 10.2.2.6 Business Strategy
      • 10.2.2.7 Recent Developments
      • 10.2.2.8 Management Change
      • 10.2.2.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.3 Otsuka
      • 10.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.3.2 Business Overview
      • 10.2.3.3 Financials (Subject to data availability)
      • 10.2.3.4 R&D Investment (Subject to data availability)
      • 10.2.3.5 Product Types Specification
      • 10.2.3.6 Business Strategy
      • 10.2.3.7 Recent Developments
      • 10.2.3.8 Management Change
      • 10.2.3.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.4 Allergan
      • 10.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.4.2 Business Overview
      • 10.2.4.3 Financials (Subject to data availability)
      • 10.2.4.4 R&D Investment (Subject to data availability)
      • 10.2.4.5 Product Types Specification
      • 10.2.4.6 Business Strategy
      • 10.2.4.7 Recent Developments
      • 10.2.4.8 Management Change
      • 10.2.4.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.5 Eli Lilly
      • 10.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.5.2 Business Overview
      • 10.2.5.3 Financials (Subject to data availability)
      • 10.2.5.4 R&D Investment (Subject to data availability)
      • 10.2.5.5 Product Types Specification
      • 10.2.5.6 Business Strategy
      • 10.2.5.7 Recent Developments
      • 10.2.5.8 Management Change
      • 10.2.5.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.6 Sunovion
      • 10.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.6.2 Business Overview
      • 10.2.6.3 Financials (Subject to data availability)
      • 10.2.6.4 R&D Investment (Subject to data availability)
      • 10.2.6.5 Product Types Specification
      • 10.2.6.6 Business Strategy
      • 10.2.6.7 Recent Developments
      • 10.2.6.8 Management Change
      • 10.2.6.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.7 Astrazeneca
      • 10.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.7.2 Business Overview
      • 10.2.7.3 Financials (Subject to data availability)
      • 10.2.7.4 R&D Investment (Subject to data availability)
      • 10.2.7.5 Product Types Specification
      • 10.2.7.6 Business Strategy
      • 10.2.7.7 Recent Developments
      • 10.2.7.8 Management Change
      • 10.2.7.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.8 Actavis Laboratories
      • 10.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.8.2 Business Overview
      • 10.2.8.3 Financials (Subject to data availability)
      • 10.2.8.4 R&D Investment (Subject to data availability)
      • 10.2.8.5 Product Types Specification
      • 10.2.8.6 Business Strategy
      • 10.2.8.7 Recent Developments
      • 10.2.8.8 Management Change
      • 10.2.8.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.9 Johnson & Johnson
      • 10.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.9.2 Business Overview
      • 10.2.9.3 Financials (Subject to data availability)
      • 10.2.9.4 R&D Investment (Subject to data availability)
      • 10.2.9.5 Product Types Specification
      • 10.2.9.6 Business Strategy
      • 10.2.9.7 Recent Developments
      • 10.2.9.8 Management Change
      • 10.2.9.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.10 Bristol Myers
      • 10.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.10.2 Business Overview
      • 10.2.10.3 Financials (Subject to data availability)
      • 10.2.10.4 R&D Investment (Subject to data availability)
      • 10.2.10.5 Product Types Specification
      • 10.2.10.6 Business Strategy
      • 10.2.10.7 Recent Developments
      • 10.2.10.8 Management Change
      • 10.2.10.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.11 Sage Therapeutics
      • 10.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.11.2 Business Overview
      • 10.2.11.3 Financials (Subject to data availability)
      • 10.2.11.4 R&D Investment (Subject to data availability)
      • 10.2.11.5 Product Types Specification
      • 10.2.11.6 Business Strategy
      • 10.2.11.7 Recent Developments
      • 10.2.11.8 Management Change
      • 10.2.11.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.12 Blackthorn Therapeutics
      • 10.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.12.2 Business Overview
      • 10.2.12.3 Financials (Subject to data availability)
      • 10.2.12.4 R&D Investment (Subject to data availability)
      • 10.2.12.5 Product Types Specification
      • 10.2.12.6 Business Strategy
      • 10.2.12.7 Recent Developments
      • 10.2.12.8 Management Change
      • 10.2.12.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.13 H Lundbeck A/S
      • 10.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.13.2 Business Overview
      • 10.2.13.3 Financials (Subject to data availability)
      • 10.2.13.4 R&D Investment (Subject to data availability)
      • 10.2.13.5 Product Types Specification
      • 10.2.13.6 Business Strategy
      • 10.2.13.7 Recent Developments
      • 10.2.13.8 Management Change
      • 10.2.13.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.14 Takeda
      • 10.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.14.2 Business Overview
      • 10.2.14.3 Financials (Subject to data availability)
      • 10.2.14.4 R&D Investment (Subject to data availability)
      • 10.2.14.5 Product Types Specification
      • 10.2.14.6 Business Strategy
      • 10.2.14.7 Recent Developments
      • 10.2.14.8 Management Change
      • 10.2.14.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      10.2.15 Cerevel Therapeutics Llc
      • 10.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 10.2.15.2 Business Overview
      • 10.2.15.3 Financials (Subject to data availability)
      • 10.2.15.4 R&D Investment (Subject to data availability)
      • 10.2.15.5 Product Types Specification
      • 10.2.15.6 Business Strategy
      • 10.2.15.7 Recent Developments
      • 10.2.15.8 Management Change
      • 10.2.15.9 S.W.O.T Analysis

  • 11.1 Market Drivers
  • 11.2 Market Restraints
  • 11.3 Market Trends
  • 11.4 Market Opportunity
  • 11.5 Technological Road Map (Subject to Data Availability)
  • 11.6 Product Life Cycle (Subject to Data Availability)
  • 11.7 Customer and Buyer Behavior Analysis
    • 11.7.1 Consumer Demographics and Target Audience Assessment
    • 11.7.2 Consumer Purchase Behavior and Demand Assessment
    • 11.7.3 Consumer Pricing Dynamics and Affordability Assessment
    • 11.7.4 Digital Consumer Engagement and Online Adoption Analysis
    • 11.7.5 Future Consumption Trends and Demand Evolution Analysis
    • 11.7.6 Enterprise Procurement & Purchasing Behavior Analysis
    • 11.7.7 Buyer Decision-Making & Purchase Influence Assessment
    • 11.7.8 Customer Expectations & Service Experience Evaluation
    • 11.7.9 Vendor Selection & Supplier Preference Analysis
    • 11.7.10 Customer Retention & Loyalty Strategy Assessment
    • 11.7.11 Pricing Sensitivity & Value Perception Analysis
    • 11.7.12 Customer Segmentation & Demand Pattern Analysis
    • 11.7.13 Relationship Management & Strategic Partnership Trends
  • 11.8 Market Attractiveness Analysis
  • 11.9 PESTEL Analysis
    • 11.9.1 Political Factors
    • 11.9.2 Economic Factors
    • 11.9.3 Social Factors
    • 11.9.4 Technological Factors
    • 11.9.5 Legal Factors
    • 11.9.6 Environmental Factors
  • 11.10 Industrial Chain Analysis (Subject to Data Availability)
    • 11.10.1 Industry Chain Analysis
    • 11.10.2 Manufacturing Cost Analysis
    • 11.10.3 Supply Side Analysis
      • 11.10.3.1 Raw Material Analysis
      • 11.10.3.2 Raw Material Procurement Analysis
      • 11.10.3.3 Raw Material Price Trend Analysis
  • 11.11 Porter’s Five Forces Analysis
    • 11.11.1 Bargaining Power of Suppliers
    • 11.11.2 Bargaining Power of Buyers
    • 11.11.3 Threat of New Entrants
    • 11.11.4 Threat of Substitutes
    • 11.11.5 Degree of Competition
  • 11.12 Patent Analysis (Subject to Data Availability)
  • 11.13 ESG Analysis

  • 12.1 Typical antipsychotics
    • 12.1.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Typical antipsychotics 2022 - 2034
    • 12.1.2 Global Neuropsychiatric Drugs Volume Market Sales by Typical antipsychotics 2022 - 2034
  • 12.2 Atypical antipsychotics
    • 12.2.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Atypical antipsychotics 2022 - 2034
    • 12.2.2 Global Neuropsychiatric Drugs Volume Market Sales by Atypical antipsychotics 2022 - 2034

  • 13.1 Bipolar disorder
    • 13.1.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Bipolar disorder 2022 - 2034
    • 13.1.2 Global Neuropsychiatric Drugs Volume Market Sales by Bipolar disorder 2022 - 2034
  • 13.2 Schizophrenia
    • 13.2.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Schizophrenia 2022 - 2034
    • 13.2.2 Global Neuropsychiatric Drugs Volume Market Sales by Schizophrenia 2022 - 2034
  • 13.3 Psychotic depression
    • 13.3.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Psychotic depression 2022 - 2034
    • 13.3.2 Global Neuropsychiatric Drugs Volume Market Sales by Psychotic depression 2022 - 2034
  • 13.4 Others
    • 13.4.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Others 2022 - 2034
    • 13.4.2 Global Neuropsychiatric Drugs Volume Market Sales by Others 2022 - 2034

  • 14.1 Parenteral route
    • 14.1.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Parenteral route 2022 - 2034
    • 14.1.2 Global Neuropsychiatric Drugs Volume Market Sales by Parenteral route 2022 - 2034
  • 14.2 Oral route
    • 14.2.1 Global Neuropsychiatric Drugs Revenue Market Size and Share by Oral route 2022 - 2034
    • 14.2.2 Global Neuropsychiatric Drugs Volume Market Sales by Oral route 2022 - 2034

  • 15.1 Company Gap Assessment Analysis
  • 15.2 Product & Service Portfolio Gap Analysis
  • 15.3 Demand-Supply Imbalance Analysis
  • 15.4 Market Opportunity & Unmet Needs Analysis
  • 15.5 Technology Adoption & Digital Transformation Gap Analysis
  • 15.6 Operational Efficiency & Process Gap Analysis
  • 15.7 Infrastructure & Capacity Gap Analysis
  • 15.8 Geographic Coverage & Distribution Gap Analysis
  • 15.9 Investment Opportunity & Funding Gap Analysis
  • 15.10 Pricing Structure & Margin Gap Analysis
  • 15.11 Innovation & R&D Capability Gap Analysis
  • 15.12 Policy, Compliance & Regulatory Gap Analysis
  • 15.13 Customer Experience & Expectation Gap Analysis
  • 15.14 Future Growth Opportunity Gap Analysis
  • 15.15 Market Accessibility & Penetration Gap Analysis

  • 16.1 Gross Margin Overview and Industry Profitability Trends
  • 16.2 Regional Gross Margin Performance Analysis
  • 16.3 Supply Chain and Distribution Impact on Gross Margins
  • 16.4 Pricing Strategy and Value-Added Margin Assessment
  • 16.5 Key Factors Influencing Gross Margin Variability
  • 16.6 Future Gross Margin Outlook and Profitability Trends

  • 17.1 Key Takeaways

  • Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

    17.2 Analyst Point of View
  • 17.3 Assumptions and Acronyms

  • 18.1 Primary Data Collection
    • 18.1.1 Steps for Primary Data Collection
      • 18.1.1.1 Identification of KOL
    • 18.1.2 Backward Integration
    • 18.1.3 Forward Integration
    • 18.1.4 How Primary Research Help Us
    • 18.1.5 Modes of Primary Research
  • 18.2 Secondary Research
    • 18.2.1 How Secondary Research Help Us
    • 18.2.2 Sources of Secondary Research
  • 18.3 Data Validation
    • 18.3.1 Data Triangulation
    • 18.3.2 Top Down & Bottom Up Approach
    • 18.3.3 Cross check KOL Responses with Secondary Data
  • 18.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research employs "The Full Truth™" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Neuropsychiatric Drugs Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 15+
Forecast Accuracy (Historical) 94.2%
Report Pages 250+
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Neuropsychiatric Drugs Market

Sources from Pharma & Healthcare Industry

How We Serve You

Three Pillars of Market Intelligence

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Neuropsychiatric Drugs Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the neuropsychiatric drugs market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report (250+ pages)
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.